Pharma: Other News To Note
Wednesday, March 28, 2012
Janssen Therapeutics, of Titusville, N.J., a unit of Johnson & Johnson, said the FDA approved Intelence (etravirine), a non-nucleoside reverse transcriptase inhibitor (NNRTI), for use in combination with other antiretroviral (ARV) medications in HIV-1 treatment-experienced pediatric patients, ages 6 to younger than 18, who are experiencing virologic failure with HIV-1 strains resistant to NNRTIs and other ARVs.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.